Brief: Mateon Therapeutics Inc Says FDA Granted Pediatric Disease Designation For OXi-4503
16/09/2020 12:23
Sept 16 (Reuters) - Mateon Therapeutics Inc MATN.PK :
* MATEON THERAPEUTICS INC - FDA GRANTED PEDIATRIC DISEASE
DESIGNATION FOR OXI-4503
Source text for Eikon: ID:nGNXbh1c0z
Further company coverage: MATN.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncotelic Therapeutics
See all newsBrief: Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation
Brief: Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026
Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
Brief: Oncotelic Announces Initiation Of Clinical Study In Non-Small Lung Cell Cancer
Brief: Oncotelic Initiates Clinical Trials Evaluating Ot-101 Against Pediatric Gliomas